| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2006: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 2005: ¥2,000,000 (Direct Cost: ¥2,000,000)
|
|---|
| Research Abstract |
Pseudomonas aeruginosa, an opportunistic pathogen, exhibits a high-level resistance to a wide variety of antibiotics that is mainly mediated by the multidrug efflux pumps in this organism. Although several RND efflux pump genes are coded in the P. aeruginosa genome, MexAB-OprM gene is only constitutively expressed. MexAB-OprM is a multicomponent efflux pump : MexB functions as a drug/proton antiporter, OprM as a channel for drugs in the outer membrane, and MexA as a linker between MexB and OprM. We focused on the OprM channel and examined its function and structure.
(1)We examined the oligomeric structure of OprM and its homologs such as OprJ and OprN by crosslinking. OprM and OprN were shown to form a trimer, but unexpectedly OprJ was found to form a tetramer, indicating that homologous outer membrane channels with the same function can assume different oligomeric structures.
(2)OprM (468 amino acids) consists of the three domains (α-helical periplasmic domain, β-barrel transmembrane do
… More
main and two extracellular loop (EL)), and two ELs consist of P100〜P109 (EL1) and R311〜G320 (EL2), respectively. In order to elucidate the function of the EL1 and EL2, we exchanged the amino acid residues of these ELs to Cys and examined the activity of MexAB-mutant OprM. It was clearly demonstrated that the mutation in the EL1 or EL2 caused the dysfunction of the pump, indicating that both EL1 and EL2 play the pivotal role in the drug extrusion by the pump. Furthermore, to be surprised, EL1 and EL2 are shown to be the sites contributing to the substrate recognition by the pump.
(3)Based on the above results, we considered that EL might become an excellent target site for the inhibitors of the efflux pump since the inhibition of the EL function could lead to the dysfunction of the pump. As EL is accessible from the outside of the cell, we though that the monoclonal antibody (mAb) can be used to interfere the EL function. Then we synthesized the peptide having the same amino acid sequence as that of EL2 and used it as an antigen. We generated the hybridomas and then their supernatants were subjected to ELISA to test the binding activity to the peptide. Up to now, we could produce 17 hybridomas secreting mAb with the binding activity to the peptide. Less
|
